AI MedBio
AI-driven antibody therapeutics for neurological diseases
Seoul, South Korea · Founded 2018
- Headquarters
- Seoul
- Founded
- 2018
- Business Model
- B2B
- Website
- aimedbio.com
- Last Round
- Corporate RoundSep 2023
- Rounds
- 1
About
AimedBio (AI MedBio) is a South Korean biotechnology company founded in 2018 as a spin-off from Samsung Medical Center. The company applies multi-omics and AI-driven big data analysis to discover and develop antibody-based therapeutics, with a focus on antibody-drug conjugates (ADCs) and bispecific antibodies targeting severe neurological diseases including brain cancer, Alzheimer's disease, and Parkinson's disease. AimedBio has entered strategic research collaborations with Samsung Biologics and AIVIS for AI-based biomarker quantification, and signed a $1B+ licensing deal with Boehringer Ingelheim for a novel ADC asset targeting solid tumors in 2025.
Summary
AI MedBio is an Artificial Intelligence company based in Seoul, South Korea, founded in 2018. Its most recent funding was a Corporate Round round in Sep 2023. Investors include Samsung Life Science Fund.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2023
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...